

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Prialt (ziconotide)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Prialt (ziconotide)

APPROVAL CRITERIA

Requests for Prialt (ziconotide) may be approved if the following criteria are met:

- I. Individuals has a diagnosis of severe chronic pain; **AND**
- II. Intrathecal therapy for chronic pain is warranted; **AND**
- III. Individual is intolerant of or refractory to other treatment, including systemic analgesics, adjunctive therapies or intrathecal morphine.

Requests for Prialt (ziconotide) may not be approved for the following:

- I. All other indications not included above; **OR**
- II. Individual is using to treat other pain types all other uses, including but not limited to post-operative pain, acute brain injury, and spasticity associated with spinal cord trauma; **OR**
- III. Individual has a pre-existing history of psychosis; **OR**
- IV. Individual has a contraindication to intrathecal administration of medications, including presence of infection at the microinfusion injection site, uncontrolled bleeding diathesis, and spinal canal obstruction that impairs circulation of cerebrospinal fluid (CSF).

Note:

Prialt (ziconotide) has a black box warning regarding the potential of neuropsychiatric adverse events. Prialt is contraindicated in those with a preexisting history of psychosis. Individuals should be monitored for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Prialt should be discontinued in the event of serious neurological or psychiatric signs or symptoms.

PAGE 1 of 2 01/14/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply. CRX-ALL-0486-20

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 9, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply. CRX-ALL-0486-20